The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include the “very rare” risk of non-arteritic anterior ischemic optic neuropathy.

The deep learning system distinguishes IIH, NAION, and healthy eyes with 93.6% accuracy, aiding in resource-limited settings.

Colombian billionaire Jaime Gilinski Bacal is open to selling his majority stake in British lender Metro Bank and has ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

EMA’s safety committee concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus & Wegovy: Amsterdam, The Netherlands Monday, June 9, 2 ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

The European Medicines Agency (EMA) has warned that popular weight-loss and diabetes drugs containing semaglutide — including ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION per the EU drug regulator. Read more here.

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...